Publications by authors named "Mathias Schroedter"
Adrenomedullin (ADM) is a vasoactive peptide in sepsis. The non-neutralizing ADM-binding antibody Adrecizumab improved outcome in animal models of systemic inflammation and sepsis. Herein, we evaluated the preclinical safety of Adrecizumab in various animal species.
View Article and Find Full Text PDFArticle Synopsis
- Adrenomedullin (ADM) plays a crucial role in maintaining the endothelial barrier during sepsis, and a humanized antibody (HAM8101) showed promising results in enhancing survival and reducing vascular dysfunction in rodent models.
- The study involved administering varying doses of HAM8101 to rats and mice, followed by tests to measure vascular leakage and key protein levels associated with kidney function post-sepsis.
- Findings revealed that HAM8101 reduced harmful protein levels while increasing protective proteins, leading to improved outcomes and survival rates in septic rodents, highlighting its potential as a therapeutic option in sepsis treatment.
Substantial attention and resources have been directed to improving outcomes of patients with critical illnesses, in particular sepsis, but all recent clinical trials testing various interventions or strategies have failed to detect a robust benefit on mortality. Acute heart failure is also a critical illness, and although the underlying etiologies differ, acute heart failure and sepsis are critical care illnesses that have a high mortality in which clinical trials have been difficult to conduct and have not yielded effective treatments. Both conditions represent a syndrome that is often difficult to define with a wide variation in patient characteristics, presentation, and standard management across institutions.
View Article and Find Full Text PDF